Brian Casey and Wayne Forrest[email protected]Clinical NewsPull linear MRI contrast from market, European group saysIn a stunning development, a European Union regulatory body on Friday recommended that four gadolinium-based contrast agents for MRI scans be pulled off the market due to concerns about gadolinium remaining in the body years after scans occur. The agents affected include some of the most widely used contrast products in medical imaging.March 9, 2017Page 1 of 1Top StoriesMolecular ImagingF-18 PSMA PET-CT proves clinical value in prostate cancerF-18 prostate-specific membrane antigen (PSMA) PET/CT is having a major impact on patient care and therapy decisions in prostate cancer, but it’s crucial to bear in mind the modality’s diagnostic quirks.Molecular ImagingCombined PET scans predict progression of Alzheimer’sMolecular ImagingPET scans predict outcomes for patients undergoing CAR T-cell therapyMRIMRI-based nomogram provides boost in breast cancerCTCT estimated to cause 5% of new cancer cases